HEALTH SCIENCES ACQUISITIONS CORPORATION INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of

HEALTH SCIENCES ACQUISITIONS CORPORATION

INDEX TO FINANCIAL STATEMENT

REPORT OF INDEPENDENT REGISTERED PUBLIC

To the Stockholders and the Board of Directors of

Health Sciences Acquisitions Corporation

Opinion on the Financial Statement

We have audited the accompanying balance

sheet of Health Sciences Acquisitions Corporation (the "Company") as of May 14, 2019, and the related notes (collectively

referred to as the "financial statement"). In our opinion, the financial statement presents fairly, in all material respects,

the financial position of the Company as of May 14, 2019, in conformity with accounting principles generally accepted in the United

This financial statement is the responsibility

of the Company's management. Our responsibility is to express an opinion on the Company's financial statement based on our audit.

We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB")

and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable

rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with

the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether

the financial statement is free of material misstatement, whether due to error or fraud. The Company is not required to have, nor

were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to

obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness

of the entity's internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures

to assess the risks of material misstatement of the financial statement, whether due to error or fraud, and performing procedures

that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures

in the financial statement. Our audit also included evaluating the accounting principles used and significant estimates made by

management, as well as evaluating the overall presentation of the financial statement. We believe that our audit provides a reasonable

basis for our opinion.

/s/ WithumSmith+Brown, PC

We have served as the Company's auditor since

HEALTH SCIENCES ACQUISITIONS CORPORATION

The accompanying notes are

an integral part of this financial statement.

HEALTH SCIENCES ACQUISITIONS CORPORATION

NOTES TO FINANCIAL STATEMENT

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Health Sciences Acquisitions

Corporation (the "Company") was incorporated in Delaware on December 6, 2018. The Company was formed for the purpose

of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business

combination with one or more businesses (the "Business Combination").

Although the Company

is not limited to a particular or geographic region for purposes of consummating a Business Combination, the Company intends to

focus on businesses in the healthcare and healthcare-related industries in North America or Europe. The Company is an emerging

growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies.

the Company had not commenced any operations. All activity for the period from December 6, 2018 (inception) through May 14, 2019

relates to the Company's formation and the initial public offering ("Initial Public Offering"), which is described

below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at

the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the

Initial Public Offering.

statement for the Company's Initial Public Offering was declared effective on May 9, 2019. On May 14, 2019, the Company consummated

the Initial Public Offering of 11,500,000 units (the "Units" and, with respect to the shares common stock included

in the Units sold, the "Public Shares"), which includes the full exercise by the underwriters of the over-allotment

option to purchase an additional 1,500,000 Units, at $10.00 per Unit, generating gross proceeds of $115,000,000, which is described

the closing of the Initial Public Offering, the Company consummated the sale of 10,000,000 warrants (the "Private Warrants")

at a price of $0.50 per Private Warrant in a private placement to Health Sciences Holdings, LLC, a Delaware limited liability company

(the "Sponsor"), generating gross proceeds of $5,000,000, which is described in Note 4.

amounted to $6,907,415, consisting of $2,300,000 of underwriting fees, $4,025,000 of deferred underwriting fees and $582,415 of

other offering costs. In addition, $2,322,592 of cash was held outside of the Trust Account (as defined below) and is available

for working capital purposes.

Following the closing

of the Initial Public Offering on May 14, 2019, an amount of $115,000,000 ($10.00 per Unit) from the net proceeds of the sale of

the Units in the Initial Public Offering and the sale of the Private Warrants was placed in a trust account ("Trust Account")

which will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company

Act of 1940, as amended (the "Investment Company Act"), with a maturity of 180 days or less or in any open-ended investment

company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined

by the Company, until the earlier of: (i) the completion of a Business Combination or (ii) the distribution of the Trust Account,

management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and

the sale of the Private Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating

a Business Combination. The Company's initial Business Combination must be with one or more target businesses that together

have a fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting fees and

taxes payable on the income earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The

Company will only complete a Business Combination if the post-transaction Company owns or acquires 50% or more of the outstanding

voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required

to register as an investment company under the Investment Company Act 1940, as amended (the "Investment Company Act").

There is no assurance that the Company will be able to complete a Business Combination successfully.

The Company will provide

its holders of the outstanding Public Shares (the "public stockholders") with the opportunity to convert all or a portion

of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called

to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder

approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The public

stockholders will be entitled to convert their Public Shares for a pro rata portion of the amount then in the Trust Account

(initially $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously

released to the Company to pay its income and franchise tax obligations). There will be no redemption rights upon the completion

of a Business Combination with respect to the Company's warrants.

The Company will proceed

with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business

Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of the Business Combination.

If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal

reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant

to the tender offer rules of the U.S. Securities and Exchange Commission ("SEC") and file tender offer documents with

the SEC prior to completing a Business Combination. If, however, stockholder approval of the transactions is required by law, or

the Company decides to obtain stockholder approval for business or legal reasons, the Company will offer to redeem shares in conjunction

with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks stockholder

approval in connection with a Business Combination, the Company's Sponsor, officers and directors (the "initial stockholders")

have agreed (i) to vote their Founder Shares (as defined in Note 4) and any Public Shares acquired in or after the Initial Public

Offering in favor of a Business Combination, (ii) not to convert any shares owned by them in connection therewith and (iii) not

to sell any of their shares to the Company in a tender offer. Additionally, each public stockholder may elect to convert their

Public Shares irrespective of whether they vote for or against the proposed transaction.

HEALTH SCIENCES ACQUISITIONS CORPORATION